Navigation Links
Arrowhead Releases New Report Assessing State of Personalized Medicine Market

The era of Personalized Medicine is set to revolutionize the healthcare industry. As our knowledge of genetics and molecular biology rapidly expands, a personalized approach to medical care is becoming increasingly important.

Minneapolis, MN (PRWEB) May 18, 2010 -- The era of Personalized Medicine is set to revolutionize the healthcare industry. As our knowledge of genetics and molecular biology rapidly expands, a personalized approach to medical care is becoming increasingly important.

Not only does this paradigm promise to improve an individual’s treatment outcome and reduce healthcare expenditure, personalized medicine is set to transform the biopharmaceutical and molecular diagnostics markets.

Arrowhead’s Personalized Medicine 2010 report provides an in-depth assessment of this burgeoning market, and examines the major challenges that need to be overcome to maximize success.

Key features of Arrowhead’s Personalized Medicine 2010 include:

Case studies of leading pharmacogenomic products
Analysis of the personalized medicine market, including seven major market sales forecasts to 2016
Regulatory and legal issues surrounding personalized medicine
Payer reimbursement challenges
Marketing strategies to capitalize profits

Key questions answered by Arrowhead’s Personalized Medicine 2010 include:

What are the major challenges in this market and how can these be overcome?
How will pharmacogenomics transform clinical trials?
What are the leading pharmacogenomic products on the market?
Who are the key players involved in the market and what strategies are they using to enhance product performance?
What pharmaceutical/biotechnology and diagnostic companies are seeking alliances in 2010?
How can company alliances maximize commercial success?

Key Findings

Rather than developing blockbuster drugs that target broad populations, in an era of personalized medicine, industry must discover and develop tailored therapies for smaller markets and the development of new therapeutics based on genomics and proteomics will require an entirely new level of tailoring.

There are many benefits associated with the pursuit of personalized medicine, among them the ability to understand risks and benefits at the level of the individual, the expanded use of biomarkers to identify unpromising drugs early in the R&D process and to run smaller, accelerated clinical trials that can be modified in mid-stream as evidence emerges.

By targeting subpopulations, the market for personalized medicine may follow the niche orphan drug structure. Currently, orphan drug status is awarded to therapeutics that target rare diseases or conditions, where the target population is less than 200,000 people. With the FDA offering funding grants for clinical research in rare diseases, this could be further incentive for personalized medicine companies wishing to gain commercial success.

Personalized medicine may breathe new life into drug programs that were abandoned during the development process or withdrawn from the market due to safety concerns.

Recommendations for Moving Forward

Articulate the benefits of products in the pipeline to payers and regulators as early as possible in the R&D process to win their support and avoid the time and expense of developing a drug or diagnostic that cannot be commercialized.

To help make the business case for reimbursement, develop health economic models that project the potential cost savings of products in development.

Work proactively with regulators to educate them about the need for a reasonable period of IP exclusivity as well as new pathways for approval of targeted diagnostics, therapeutics and MTT companion diagnostics. Assist in offering novel solutions.

Collaborate with payers in developing novel reimbursement strategies that minimize your risks and costs, such as an accelerating schedule of reimbursements as products progress through their lifecycle and demonstrate their efficacy.

For more information about this report, please CLICK HERE or contact us at 312-244-3703.

# # #

Read the full story at

Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related biology technology :

1. The Biggest Names in the Field of Personalized Medicine to Speak at Arrowhead's Upcoming 2009 Personalized Medicine Conference
2. Vital Images Releases Next Generation Enterprise-Wide Solutions Featuring Vitrea(R) 4.0 and ViTALConnect(R) 4.1
3. Quigley Corporation Releases Update on Quigley Pharmas Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
4. Boston Scientific Releases Remote Monitoring Data from its Wireless LATITUDE(R) Patient Management System
5. ARUP Laboratories Releases ARUP Consult(R) 2.0
6. Rabobank Releases Annual North American Food & Agribusiness Outlook
7. National Nanotechnology Initiative releases new strategic plan
8. Seven Summits Research Releases Alerts on XOM, MER, DRYS, CSC, and PDLI
9. CellCyte Genetics Corp. Responds to Plaintiff Law Firm Press Releases
10. BioTrends Releases Fourth Annual Nephrology TreatmentTrends Publication Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
11. Clontech Laboratories, Inc. Releases the ProteoTuner(TM) Systems
Post Your Comments:
(Date:11/30/2015)... ... November 30, 2015 , ... ... exhibition Jurassic World: The Exhibition, opening in March 2016 at Melbourne Museum in ... worldwide tour including several North American tour dates. The Exhibition is based on ...
(Date:11/30/2015)... -- HUYA Bioscience International, the leader in accelerating global development ... announced it has signed a Memorandum of Understanding with ... between KDDF and HUYA with the ultimate goal of ... the global market. China,s ... preclinical and clinical stage compounds. The company advances the ...
(Date:11/30/2015)... 30, 2015  Northwest Biotherapeutics (NASDAQ: NWBO ) ... immune therapies for solid tumor cancers, announced today that ... director, and the Company welcomes Neil Woodford,s ... recent anonymous internet report on NW Bio.  The Company,s ... Linda Powers stated, "We agree with Mr. Woodford ...
(Date:11/27/2015)... 27, 2015 /PRNewswire/--  Mallinckrodt plc (NYSE: MNK ... it has closed the sale of its global contrast ... NYSE Euronext) in a transaction valued at approximately $270 ... and a total of approximately 1,000 employees spread across ... St. Louis area. This entire workforce and ...
Breaking Biology Technology:
(Date:11/10/2015)... 2015 About signature verification ... to identify and verify the identity of an ... the secure and accurate method of authentication and ... individual because each individual,s signature is highly unique. ... dynamic signature of an individual is compared and ...
(Date:11/2/2015)...  SRI International has been awarded a contract of ... to the National Cancer Institute (NCI) PREVENT Cancer Program ... modern testing and support facilities, and analytical instrumentation to ... studies to evaluate potential cancer prevention drugs. ... Drug Development Program is an NCI-supported pipeline to bring ...
(Date:10/29/2015)... , Oct. 29, 2015  Rubicon Genomics, ... for U.S. distribution of its DNA library preparation ... and Rubicon,s new ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq ... the preparation of NGS libraries for liquid biopsies--the ... diagnostic and prognostic applications in cancer and other ...
Breaking Biology News(10 mins):